The results from this study warrant further investigation into the therapeutic potential of PDIA-4 for treating impaired autophagy-, impaired endothelial dysfunction-, and/or EndMT-associated diseases, such as atherosclerosis and organ fibrosis. This evidence concerns the gene PDIA4 and endothelial dysfunction.